Chemical inhibitors of 1700008B15Rik can exert their effects through various mechanisms by specifically targeting pathways essential for the protein's function. Staurosporine acts as a potent protein kinase inhibitor, thus it can inhibit key phosphorylation events that 1700008B15Rik may rely on for its activity or interaction with other cellular components. Similarly, both Wortmannin and LY294002 serve as inhibitors of PI3K, a kinase that participates in signaling cascades which could regulate the function of 1700008B15Rik, likely by altering the phosphorylation status of either the protein itself or related substrates that dictate its activity.
In the realm of the MAPK/ERK pathway, PD98059 and U0126 are noteworthy as they inhibit MEK, an upstream kinase that could phosphorylate substrates impacting 1700008B15Rik's function. By inhibiting MEK, these chemicals may prevent the activation of downstream targets that are crucial for the protein's biological role. In a similar fashion, SB203580's specific inhibition of p38 MAP kinase and SP600125's inhibition of JNK can interrupt the pathways that might regulate stress response and apoptosis, thereby modulating the function of 1700008B15Rik. Moreover, the chemicals Erlotinib, Gefitinib, and Lapatinib focus on inhibiting EGFR tyrosine kinase, whose activity can be integral for the signaling pathways involving 1700008B15Rik, resulting in the downregulation of its activity. The dual tyrosine kinase inhibitor Lapatinib expands this inhibition to HER2/neu, which could further disrupt the complex signaling network 1700008B15Rik functions within.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits protein kinases, which could be crucial for 1700008B15Rik function by phosphorylating the protein or related signaling components. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits PI3K, which may be part of the signaling pathway required for 1700008B15Rik to exert its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, and by inhibiting this kinase, it can prevent the activation of downstream targets necessary for 1700008B15Rik function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is involved in the MAPK/ERK pathway, possibly a pathway for 1700008B15Rik function by affecting its phosphorylation state. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 also targets MEK in the MAPK/ERK pathway, potentially leading to inhibition of 1700008B15Rik activity by preventing its activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which may play a role in the functional regulation of 1700008B15Rik through stress response pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, possibly involved in the stress and apoptosis pathways that could regulate the function of 1700008B15Rik. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib inhibits EGFR tyrosine kinase, which may be involved in signal transduction pathways essential for 1700008B15Rik function. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib targets EGFR tyrosine kinase, and inhibition of this pathway could lead to functional inhibition of 1700008B15Rik. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets EGFR and HER2/neu which are potentially involved in pathways necessary for 1700008B15Rik function. | ||||||